References:

1.
Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008:158-166.
2.
Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute website. http://seer.cancer.gov/csr/1975_2011/results_single/sect_19_table.29_2pgs.pdf. Updated December 17, 2014. Accessed February 25, 2015.
3.
Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute website. http://seer.cancer.gov/csr/1975_2011/results_merged/topic_med_age.pdf. Updated December 17, 2014. Accessed February 25, 2015.
4.
Fameli-Pavlaki M. Diffuse large B-cell lymphoma–part I: towards homogeneity. Haema. 2005;8:201-214.
5.
Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011:498-505.
6.
Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417-1429.
7.
Wilson WH. Treatment strategies for aggressive lymphomas: what works? Hematology Am Soc Hematol Educ Program. 2013:584-590.
8.
Narayanan S, Savage KJ. Staging and prognostic factors. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R, eds. Non-Hodgkin Lymphomas. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:149-171.
9.
Armitage JO, Mauch PM, Harris NL, Dalla-Favera R, Bierman PJ. Diffuse large B-cell lymphoma. In: Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R, Harris NL, eds. Non-Hodgkin Lymphomas. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:304-326.
10.
Manson SD, Porter C. Lymphomas. In: Yarbro CH, Frogge MH, Goodman M, eds. Cancer Nursing: Principles and Practice. 6th ed. Sudbury, MA: Jones & Bartlett Publishers; 2005:1414-1459.
11.
Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014;89:310-314.
12.
From the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Hodgkin's Lymphomas V.2.2015. © National Comprehensive Cancer Network, Inc. 2015. All rights reserved. Accessed March 9, 2015. To view the most recent and complete version of the guidelines, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
13.
Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med. 2008;132:118-124.
14.
Good DJ, Gascoyne RD. Diagnosis: diagnostic procedures, histopathologic problems, immunophenotyping, and applied genetics. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R. Non-Hodgkin Lymphomas. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:132-148.
15.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059-3068. doi:10.1200/JCO.2013.54.8800.
16.
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
17.
Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.
18.
Lenz G, Nagel I, Siebert R, et al. Aberrent immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma. J Exp Med. 2007;204:633-643.
19.
Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460-3467.
20.
Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253-2263. doi:10.1182/blood-2012-06- 435842.
21.
Tilly H, Dreyling M; for ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(suppl 4):iv110-iv112.
22.
Sweetenham JW. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program. 2005;252-259.
23.
Moskowitz CH. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation. Ann Oncol. 2006;17(suppl 4):iv37-iv39.
24.
Mey UJM, Jha V, Strehl JW, et al. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. German Med Sci. 2007;5:1-11.
25.
Westin JR, Neelapu SS. Therapy of newly diagnosed follicular lymphoma. Front Oncol. 2012;2:1-7.
26.
Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol. 2011;24(2):147-163. doi:10.1016/j.beha.2011.02.006.
27.
Freedman AS. Biology and management of histologic transformation of indolent lymphoma. Hematology Am Soc Hematol Educ Program. 2005:314-320.
28.
Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005;106:1164-1174.
29.
US National Institutes of Health. ClinicalTrials.gov website. http://www.clinicaltrials.gov. Accessed February 3, 2014.
30.
Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville, MD: Food and Drug Administration; May 2007.
31.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. doi:10.1200/JCO.2006.09.2403.

Explore BioOncology Resources by Tumor Type

X

Use this Related Resources tool to quickly access topics of interest throughout the site that are relevant to a tumor type.

Select a tumor type to get started

: Related Resources

Learn more about

Tumor Types